CANCER BUZZ
Of the barriers to innovation and adopting new strategies, human hesitation is one of the greatest. Health care is a rapidly evolving field by nature, which is compounded by near constant technological advancement. For insight into overcoming hesitation while navigating frequent change in a burnout-oriented industry, CANCER BUZZ spoke with Michelle Rozen, PhD, behavioral scientist, bestselling author, and keynote speaker at the upcoming 2026 ACCC Leadership Summit. Dr. Rozen shares concrete strategies that oncology leaders can implement in their programs to not just survive, but thrive in an...
info_outlineCANCER BUZZ
In the second installment of Oncology Unscripted, an unfiltered, honest dialogue about the state of cancer care today, hosts Mark Liu and Deirdre Saulet invite Meagan O’Neill, MS, Executive Director of ACCC, to discuss the Association’s plans for the upcoming year, honing in on challenges and opportunities within its membership. O’Neill shares the vision behind expanding the CANCER BUZZ podcast, the continued development of ACCC’s 2030 vision, and how she views crisis as a path forward for innovation. “When I look at 2026, [I look] at crisis as an opportunity...How can we use this...
info_outlineCANCER BUZZ
Advanced practice providers (APPs) are both an integral part of the care team and a driving force behind innovation in oncology. This special state society episode of CANCER BUZZ will explore how oncology APPs are stepping into leadership roles—formally and informally—to advocate for role clarity and equitable compensation, improve mentorship, and elevate the value of APPs within the multidisciplinary cancer care team. Jessica Leibelt, AGNP-C, AOCNP, from Fred Hutchinson Cancer Center, Carlin Callaway, DMP, RN, ACNP-BC, ACNS-BC, AOCNP, from the University of Colorado Cancer Center, and...
info_outlineCANCER BUZZ
Cancer cases, cancer-related deaths, and survivorship are projected to rise exponentially—yet oncology faces critical workforce shortages. In this episode, CANCER BUZZ speaks with Tristan Blanco, a biology major and fellow in VCU Massey’s Cancer-focused Undergraduate Research Experience (CURE) Program, who shares his experience as part of a program designed to scale oncology education and meet the evolving needs of cancer care nationwide. Get behind the scenes of an innovative training model that’s preparing the next generation of oncology leaders. "It’s one of the smartest ways...
info_outlineCANCER BUZZ
Introducing a brand new podcast from ACCC: Oncology Unscripted. In this inaugural episode, hosts Mark Liu and Deirdre Saulet lay out what listeners can expect from the show, including unfiltered, honest dialogue about the state of cancer care today, the most pressing challenges providers are facing, and how they can move forward with hope amid unpredictable headwinds. Liu and Saulet will approach a variety of topics, from operational to financial to clinical, as they explore how providers can help one another, continue to hold important conversations, and act as agents of change in oncology....
info_outlineCANCER BUZZ
CAR T-cell therapy is a potentially life-saving treatment for patients with certain hematologic malignancies. Yet, the logistical challenges and the need for specialized management of adverse events have limited its availability in community settings. In this episode, CANCER BUZZ speaks with Jeremy M. Pantin, MD, FACP, clinical director of the Adult Transplant and Cellular Therapy Program at TriStar Centennial Medical Center, part of the Sarah Cannon Transplant and Cellular Therapy Network. Dr. Pantin discusses the cancer center’s community-based, outpatient model, impact on outcomes for...
info_outlineCANCER BUZZ
Claudin 18.2 is a novel biomarker for advanced gastric and gastroesophageal junction cancer. Patients who test positive for claudin 18.2 may be candidates for the monoclonal antibody, zolbetuximab, which directly targets this biomarker. In this episode, CANCER BUZZ speaks with Manish A. Shah, MD, FASCO, director of the Gastrointestinal Oncology Program at Weill Cornell Medicine, about how claudin 18.2 is shaping treatment decisions and some of the clinical trials pursuing more information about the potential for this biomarker. CANCER BUZZ also speaks with Sasha Watson, PharmD, outpatient...
info_outlineCANCER BUZZ
Relapsed/refractory follicular lymphoma (R/R FL) is challenging to treat, requiring thoughtful clinical decision-making during treatment selection and sequencing. In this episode, CANCER BUZZ speaks with Benjamin Heyman, MD, hematologist and clinical associate professor at City of Hope, about the importance of individualized care, shared decision-making, clinical trial referrals, and multidisciplinary collaboration. CANCER BUZZ also speaks with Laurie Adami, patient advocate with R/R FL, about her real-world experience with multiple lines of therapy, clinical trials, and patient advocacy. ...
info_outlineCANCER BUZZ
After 6 years of bringing listeners key insights into the most pressing topics in oncology, ACCC’s podcast, CANCER BUZZ, has gotten a facelift! In this episode, CANCER BUZZ brings back our first podcast guest, Tina Curtis, DNP, MBA, RN, NEA-BC, executive director of cancer services at Froedtert Hospital. In the June 26, 2019, inaugural CANCER BUZZ episode, Dr. Curtis spoke about her institution’s 24-hour, oncology-only urgent care clinic, which earned the cancer program a 2018 ACCC Innovator Award. Today, she’s returned with her colleague Jayme Cotter to share an update on that program,...
info_outlineCANCER BUZZ
US Veterans are at a heightened risk for lung cancer due to service-related exposures. Integrating clinical research into routine oncology care at the US Department of Veterans Affairs (VA) can help bring clinical trials closer to where Veterans live and improve access to cutting edge therapies. In this episode, CANCER BUZZ speaks with Millie Das, MD, chief of oncology at the VA Palo Alto Health Care System, about the collaborations and institutional support that allowed them to launch lung cancer clinical trials and the role industry has played. “My primary motivation...
info_outlineClaudin 18.2 is a novel biomarker for advanced gastric and gastroesophageal junction cancer. Patients who test positive for claudin 18.2 may be candidates for the monoclonal antibody, zolbetuximab, which directly targets this biomarker. In this episode, CANCER BUZZ speaks with Manish A. Shah, MD, FASCO, director of the Gastrointestinal Oncology Program at Weill Cornell Medicine, about how claudin 18.2 is shaping treatment decisions and some of the clinical trials pursuing more information about the potential for this biomarker. CANCER BUZZ also speaks with Sasha Watson, PharmD, outpatient medical oncology clinical pharmacist at Sylvester Comprehensive Cancer Center, about the importance of engaging the whole multidisciplinary team in biomarker testing for optimal patient outcomes.
“I often talk to my gastroenterologist and ask them to get more than 1 biopsy to make sure that we have enough tissue for now and even in the future.” - Manish A. Shah, MD, FASCO
Instead of lumping all gastric cancers into one group, we use these biomarkers to split them out... We have more refined and tailored treatments for patients with gastroesophageal adenocarcinoma based on these biomarkers.” - Manish A. Shah, MD, FASCO
“Nurses in the infusion center are a huge help that we absolutely need, and administering this treatment would be very difficult if we didn't have scaled and experienced nurses here.” - Aleksandra (Sasha) Watson, PharmD
“What I see is just a lot of patients having hope—some new part of their cancer that we can target with a drug that we previously didn't have any options for.” - Aleksandra (Sasha) Watson, PharmD
Guests:
Manish A. Shah, MD, FASCO
Director, Gastrointestinal Oncology Program
Weill Cornell Medicine
New York, NY
Aleksandra (Sasha) Watson, PharmD
Outpatient Medical Oncology Clinical Pharmacist (GI + Sarcoma)
Sylvester Comprehensive Cancer Center
Miami, FL
Resources